消瘤汤联合mFOLFOX6方案治疗Ⅲ期结直肠癌临床效果分析

Clinical efficacy of Xiaoliu decoction combined with mFOLFOX6 regimen in stageⅢcolorectal cancer

目的探讨消瘤汤联合化疗治疗Ⅲ期结直肠癌临床效果,为Ⅲ期结直肠癌患者的治疗提供依据。方法对2017年2月至12月我院收治的临床资料完整的40例Ⅲ期结直肠癌患者进行回顾性研究分析。40例患者分为观察组和对照组,每组20例。对照组患者使用mFOLFOX6化疗方案进行治疗,观察组患者使用消瘤汤和mFOLFOX6化疗方案进行治疗。治疗结束后,对比2组患者治疗疗效、化疗产生的不良反应和生活质量的变化,从而评价临床疗效及安全性。结果①治疗后血清肿瘤标志物癌胚抗原(CEA)、糖类抗原(CA)199值均较治疗前显著降,观察组血清CEA、CA199值下降更显著(P<0.05);②观察组患者治疗的总有效率明显高于对照组患者(P<0.05)。③治疗前,2组患者体力情况的评分和生活质量的评分相比差异无统计学意义(P>0.05)。治疗后,2组患者体力情况的评分和生活质量的评分均较治疗前有提升,其中观察组患者治疗后体力情况的评分和生活质量的评分均明显高于对照组患者(P<0.05)。④观察组患者不良反应发生率显著低于对照组患者(P<0.05)。结论消瘤汤联合mFOLFOX6方案化疗能减轻Ⅲ期结直肠癌患者的临床症状,降低血清CEA、CA199水平,改善细胞免疫水平,提升近期有效率、生活质量及体力水平,同时会减轻化疗过程中发生的部分毒副反应,具有减毒增效的作用。

Objective To investigate the clinical efficacy of Xiaoliu decoction combined with chemotherapy in the treatment of stageⅢcolorectal cancer,and to provide evidence for the treatment of stageⅢcolorectal cancer.Methods A retrospective study was conducted for 40 patients who presented complete clinical data of stageⅢcolorectal cancer treated in our hospital between February 2017 and December 2017.The patients were randomized into the study group and control group(n=20 each).Patients in the control group were treated with mFOLFOX6 chemotherapy,while those in the study group were treated with Xiaoliu decoction and mFOLFOX6 chemotherapy.After the treatment,the two groups of patients were compared for the treatment response,chemotherapy-related adverse reactions and changes in the quality of life,for assessment of the clinical efficacy and safety.Results①The both groups showed significantly reduced levels of serum tumor markers(CEA and CA199)after treatment compared with baseline,and the reductions in serum CEA and CA199 levels were greater in the study group compared with the control group(P<0.05).②The total rate of response in the study group was significantly higher than that in the control group(P<0.05).③Before treatment,there were no significant differences in scores of physical performance and quality of life between the two groups of patients(P>0.05).After treatment,the scores of physical performance and quality of life in either group were improved compared with baseline,and the scores were significantly higher in the study group than those in the control group(P<0.05).④Adverse reactions were significantly less in the study group compared with the control group(P<0.05).Conclusion In patients with stageⅢcolorectal cancer,Xiaoliu decoction combined with mFOLFOX6 chemotherapy can alleviate clinical symptoms,reduce serum CEA and CA199 levels,improve cellular immunity,increase short-term response rate,quality of life and physical performance.To a certain extent,the combination therapy is associated with less toxic and side effects related to chemotherapy,and therefore appears toxicity-attenuated and efficacy-enhanced.